SCHEMBL2216196

SCHEMBL2216196

Nc1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc(-c5ccccc5)c4)cc4ccnn34)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 2/20 0.45
SETD7 Q8WTS6 1/20 0.45
POLB P06746 3/20 0.44
MAPT P10636 3/20 0.44
PLAU P00749 1/20 0.42
DNMT1 P26358 1/20 0.42
ABL1 P00519 2/20 0.42
BCR P11274 2/20 0.42
ABL2 P42684 1/20 0.42
HDAC1 Q13547 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
APEX1 P27695 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
STAT3 P40763 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2214589 0.91 HDAC1 (0.45) POLBMAPTPLAUHDAC1STAT3
SCHEMBL2213308 0.90 MPL (0.43) PRMT1SETD7POLBMAPTPLAU
SCHEMBL2211981 0.86 HDAC1 (0.45) POLBMAPTPLAUHDAC1MEN1
SCHEMBL2214607 0.82 PLAU (0.46) POLBMAPTPLAUMEN1LMNA
SCHEMBL2215099 0.82 POLB (0.47) POLBMAPTMEN1KMT2ATDP1
SCHEMBL2214976 0.81 MAPT (0.47) POLBMAPTPLAUHDAC1MEN1
SCHEMBL2214363 0.81 HDAC1 (0.42) PLAUHDAC1MEN1KMT2ASMN1; SMN2
SCHEMBL2214950 0.81 PTPN1 (0.46) PLAUHDAC1MEN1KMT2ANR1H4
SCHEMBL2880155 0.80 PLK1 (0.43) MAPTMEN1PKMKMT2ANPSR1
SCHEMBL2214233 0.80 DNMT1 (0.42) POLBMAPTDNMT1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 PRMT1 814/4885SETD7 4079/4885POLB 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.